ABT vs AUPH · P/E 25, rev $44.33B vs P/E 28, rev $160.9M
Abbott Laboratories (ABT) versus Aurinia Pharmaceuticals Inc (AUPH) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Aurinia Pharmaceuticals Inc (AUPH) is a biotechnology company listed on US.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported AUPH revenue for 2026-06-30 was $160.9M. Net income was $71.8M. AUPH currently screens at market cap $1.03B and trailing P/E 28.1.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. AUPH currently screens at market cap $1.03B and trailing P/E 28.1.
Not investment advice. Open the ABT and AUPH stock pages for the full models.
Not investment advice.